Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of Omegaven™ Parenteral Nutrition in Patients With TPN-Induced Cholestasis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2009 by University of Nebraska.
Recruitment status was:  Enrolling by invitation
Sponsor:
Information provided by:
University of Nebraska
ClinicalTrials.gov Identifier:
NCT00826020
First received: January 15, 2009
Last updated: May 4, 2009
Last verified: May 2009

January 15, 2009
May 4, 2009
April 2009
August 2013   (Final data collection date for primary outcome measure)
Progression to small bowel transplantation. [ Time Frame: Bi-weekly x4, then monthly ]
Same as current
Complete list of historical versions of study NCT00826020 on ClinicalTrials.gov Archive Site
To determine if established PN associated liver disease can be reversed or its progression halted by using a fish oil parenteral emulsion as measured by normalization of serum levels of hepatic enzymes and bilirubin. [ Time Frame: weekly x 4, then bi-weekly x4, then monthly ]
Same as current
Not Provided
Not Provided
 
Evaluation of Omegaven™ Parenteral Nutrition in Patients With TPN-Induced Cholestasis
Prospective Evaluation of a Parenteral Omega-3 Fatty Acid Preparation (Omegaven™) in Therapy of Patients With TPN-Induced Cholestasis
The purpose of this study is to determine if established parenteral nutrition (PN) associated liver disease can be reversed or its progression halted by using a parenteral fat emulsion prepared from fish oil as measured by normalization of serum levels of hepatic enzymes and bilirubin.
Not Provided
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Parenteral Nutrition Associated Liver Disease PNALD
  • Cholestasis
Drug: Omegaven™
10% Omegaven™, 50 or 100 mL bottle; 1gram/kg/day and is infused over 12-24 hours.
Other Name: Omega-3 fat emulsion
Experimental: Omegaven™
Intervention: Drug: Omegaven™

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
100
August 2013
August 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must be enrolled in the Intestinal Rehabilitation Program at the University of Nebraska Medical Center, AND:
  • Be unable to meet nutritional needs solely by enteral nutrition and be expected to require PN for at least another 30 days
  • Have clinical evidence of parenteral nutrition associated liver disease (PNALD) as defined as a direct bilirubin of 2 mg/dl or more. A liver biopsy is desirable but not necessary for treatment
  • Signed patient informed consent

Exclusion Criteria:

  • Parent or guardian or child unwilling to provide consent or assent
  • Inability or unwillingness on the part of parent/guardian or child to follow clinical recommendations of the Intestinal Rehabilitation Program
  • Allergies or clinical conditions precluding safe use of Omegaven™
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00826020
084-09-FB
Yes
Not Provided
Not Provided
Not Provided
David Mercer, MD, PhD, University of Nebraska Medical Center
University of Nebraska
Not Provided
Principal Investigator: David F Mercer, MD, PhD University of Nebraska
University of Nebraska
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP